.Pharmacolibrary.Drugs.ATC.B.B01AE06

Information

Bivalirudin is a synthetic 20-amino acid polypeptide direct thrombin inhibitor used as an anticoagulant, mainly in the setting of percutaneous coronary intervention (PCI), and approved for use as an alternative to heparin, particularly in patients with or at risk for heparin-induced thrombocytopenia. It is approved by the FDA and used in current clinical practice.

Pharmacokinetics

Pharmacokinetics in adult patients undergoing percutaneous coronary intervention, both male and female, normal renal and hepatic function.

References

1. Zhang, DM, et al., & Cui, YM (2012). Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers. Acta pharmacologica Sinica 33(11) 1387–1394. DOI:10.1038/aps.2012.37 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22659624

2. Zhang, D, et al., & Cui, Y (2011). Pharmacokinetics, pharmacodynamics, tolerability and safety of single doses of bivalirudin in healthy chinese subjects. Biological & pharmaceutical bulletin 34(12) 1841–1848. DOI:10.1248/bpb.34.1841 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22130240

3. Scandroglio, AM, et al., & Pappalardo, F (2021). Impact of CytoSorb on kinetics of vancomycin and bivalirudin in critically ill patients. Artificial organs 45(9) 1097–1103. DOI:10.1111/aor.13952 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33686696

Revisions

• 06/2025 initial generated model